Neuroderm Revenue and Competitors
Estimated Revenue & Valuation
- Neuroderm's estimated annual revenue is currently $40.6M per year.
- Neuroderm's estimated revenue per employee is $201,000
Employee Data
- Neuroderm has 202 Employees.
- Neuroderm grew their employee count by 0% last year.
Neuroderm's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Project Management Officer | Reveal Email/Phone |
2 | Head Product Management | Reveal Email/Phone |
3 | Head RA Device | Reveal Email/Phone |
4 | Device Operational Excellence Sr. Director | Reveal Email/Phone |
5 | Programs and Systems Engineering Sr Director | Reveal Email/Phone |
6 | Director Quality Compliance | Reveal Email/Phone |
7 | Director, Head Supply Chain & NPI | Reveal Email/Phone |
8 | Director Regulatory Affairs | Reveal Email/Phone |
9 | Device Projects Director | Reveal Email/Phone |
10 | Director - Head Pharmaceutical research | Reveal Email/Phone |
Neuroderm Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Neuroderm?
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients' lives. NeuroDerm's technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
keywords:N/A
N/A
Total Funding
202
Number of Employees
$40.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neuroderm News
NeuroDerm's Drug-Device Combo Product for Parkinson's Disease. NeuroDerm presented positive, long-term safety and tolerability data for...
NeuroDerm presents data at 2022 American Academy of Neurology Annual Meeting. Long-term safety data from the Phase 2b BeyoND study...
NeuroDerm Ltd: Israel-based NeuroDerm announced positive, long-term data for Parkinson's disease-aimed asset ND0612 at the American Academy...
Other Companies in Rehovot
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $69.8M | 235 | -15% | N/A |